rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
2005-3-1
|
pubmed:abstractText |
The objective of this study was to conduct a cost-effectiveness analysis of Herceptin from the hospital's point of view. This new biotechnological pharmaceutical is a humanized monoclonal antibody that targets the HER2 receptor, an important anti-cancer target.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0266-4623
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
21
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
132-7
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:15736525-Antibodies, Monoclonal,
pubmed-meshheading:15736525-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15736525-Antineoplastic Agents,
pubmed-meshheading:15736525-Belgium,
pubmed-meshheading:15736525-Breast Neoplasms,
pubmed-meshheading:15736525-Costs and Cost Analysis,
pubmed-meshheading:15736525-Female,
pubmed-meshheading:15736525-Humans,
pubmed-meshheading:15736525-Technology Assessment, Biomedical
|
pubmed:year |
2005
|
pubmed:articleTitle |
Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital.
|
pubmed:affiliation |
Department of Economics, Ghent University, Belgium. mattias.neyt@ugent.be
|
pubmed:publicationType |
Journal Article
|